Precision Antibody contributes to the development of novel antibody reagents for the RAS signaling network
The National Cancer Institute (NCI)’s RAS initiative has been working with the Office of Cancer Clinical Proteomics Research (OCCPR) to launch a proteomic assay development and characterization project targeting RAS-associated pathways. The goal of this research, which aligns with one of NCI-OCCPR’s missions of providing publicly accessible, well-characterized reagents and resources for the cancer research community, is to develop, validate, and distribute monoclonal antibodies. These antibodies will enable the enrichment and detection of proteins and post-translational modifications involved in RAS signal transduction. Precision Antibody developed the antibody described in this manuscript.
To read the full Nature article, please download here.
